Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551

Tiziana Mennini, Anna Miari, Maria Laura Presti, Massimo Rizzi, Rosario Samanin, Annamaria Vezzani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic treatment of adult rats with dl-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic carboxyethylester (CGP 39551) (30 mg/kg orally for 12 days) induced a significant increase, 72 h after the last dose, in the N-methyl-d-aspartate (NMDA)-sensitive [3H]glutamate binding in the hippocampal pyramidal layer (stratum oriens CA1, CA3: + 51% on average; stratum radiatum CA1, CA3: +40% on average; stratum pyramidale CA1: +20%, CA3: + 55%) and in the dentate gyrus (+43%) compared to vehicle-injected animals, as assessed by quantitative receptor autoradiography. Similar results were obtained using the NMDA receptor antagonist, [3H]DL-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 396653). Saturation experiments showed that the increase in [3H]CGP 39653 binding was due to the maximum number of receptors, without changes in affinity. The same regimen did not alter [3H]N-(1-[2-thienyl]-cyclohexyl)-3, 4-piperidine (TCP) binding to the ion channel coupled to the receptor but prevented D-serine (5 μM)-induced enhancement of [3H]glutamate binding. NMDA (3-300 μM) enhanced [3H]noradrenaline release from hippocampal slices, and 7-Cl-kynurenic acid (5-100 μM) and (+)-5-methyl-10, 11-dihydro-5H-dibenzo- [a,d]cyclo-hepten-5, 10-imine maleate (MK 801) (0.03-0.3 μM), antagonists at the glycine site and ion channel respectively, antagonized this effect to the same extent in CGP 39551-treated rats and controls. Chronic CGP 39551 did not affect the neurotoxic potency of quinolinic acid, a selective agonist at the NMDA receptor, injected in the hippocampus. The sensitivity of the NMDA receptor complex to selective agonists or antagonists, thus, does not appear to be altered by chronic treatment with CGP 39551 in adult rats in spite of an increase in the density of the agonist recognition sites. Therefore tolerance is not likely to develop to the pharmacological actions of the drug, and endogenously released excitatory amino acids should not have deleterious effects due to their interaction with a higher amount of NMDA receptors after withdrawal of CGP 39551.

Original languageEnglish
Pages (from-to)93-101
Number of pages9
JournalEuropean Journal of Pharmacology
Volume271
Issue number1
DOIs
Publication statusPublished - Dec 12 1994

Fingerprint

CGP 39551
Hippocampus
Hippocampal CA1 Region
Ion Channels
Aspartic Acid
Glutamic Acid
Hippocampal CA3 Region
Kynurenic Acid
Quinolinic Acid
Excitatory Amino Acids
Imines
Dizocilpine Maleate
Dentate Gyrus
Autoradiography
Glycine
Serine
Norepinephrine
aspartic acid receptor
Pharmacology

Keywords

  • Autoradiography
  • Chronic CGP 39551
  • Hippocampus
  • NMDA receptor
  • Quinolinic acid neurotoxicity
  • [H]Noradrenaline release

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551. / Mennini, Tiziana; Miari, Anna; Presti, Maria Laura; Rizzi, Massimo; Samanin, Rosario; Vezzani, Annamaria.

In: European Journal of Pharmacology, Vol. 271, No. 1, 12.12.1994, p. 93-101.

Research output: Contribution to journalArticle

Mennini, Tiziana ; Miari, Anna ; Presti, Maria Laura ; Rizzi, Massimo ; Samanin, Rosario ; Vezzani, Annamaria. / Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551. In: European Journal of Pharmacology. 1994 ; Vol. 271, No. 1. pp. 93-101.
@article{fedfb58c5ea5401db8b65d7c6c8e719c,
title = "Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551",
abstract = "Chronic treatment of adult rats with dl-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic carboxyethylester (CGP 39551) (30 mg/kg orally for 12 days) induced a significant increase, 72 h after the last dose, in the N-methyl-d-aspartate (NMDA)-sensitive [3H]glutamate binding in the hippocampal pyramidal layer (stratum oriens CA1, CA3: + 51{\%} on average; stratum radiatum CA1, CA3: +40{\%} on average; stratum pyramidale CA1: +20{\%}, CA3: + 55{\%}) and in the dentate gyrus (+43{\%}) compared to vehicle-injected animals, as assessed by quantitative receptor autoradiography. Similar results were obtained using the NMDA receptor antagonist, [3H]DL-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 396653). Saturation experiments showed that the increase in [3H]CGP 39653 binding was due to the maximum number of receptors, without changes in affinity. The same regimen did not alter [3H]N-(1-[2-thienyl]-cyclohexyl)-3, 4-piperidine (TCP) binding to the ion channel coupled to the receptor but prevented D-serine (5 μM)-induced enhancement of [3H]glutamate binding. NMDA (3-300 μM) enhanced [3H]noradrenaline release from hippocampal slices, and 7-Cl-kynurenic acid (5-100 μM) and (+)-5-methyl-10, 11-dihydro-5H-dibenzo- [a,d]cyclo-hepten-5, 10-imine maleate (MK 801) (0.03-0.3 μM), antagonists at the glycine site and ion channel respectively, antagonized this effect to the same extent in CGP 39551-treated rats and controls. Chronic CGP 39551 did not affect the neurotoxic potency of quinolinic acid, a selective agonist at the NMDA receptor, injected in the hippocampus. The sensitivity of the NMDA receptor complex to selective agonists or antagonists, thus, does not appear to be altered by chronic treatment with CGP 39551 in adult rats in spite of an increase in the density of the agonist recognition sites. Therefore tolerance is not likely to develop to the pharmacological actions of the drug, and endogenously released excitatory amino acids should not have deleterious effects due to their interaction with a higher amount of NMDA receptors after withdrawal of CGP 39551.",
keywords = "Autoradiography, Chronic CGP 39551, Hippocampus, NMDA receptor, Quinolinic acid neurotoxicity, [H]Noradrenaline release",
author = "Tiziana Mennini and Anna Miari and Presti, {Maria Laura} and Massimo Rizzi and Rosario Samanin and Annamaria Vezzani",
year = "1994",
month = "12",
day = "12",
doi = "10.1016/0014-2999(94)90269-0",
language = "English",
volume = "271",
pages = "93--101",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551

AU - Mennini, Tiziana

AU - Miari, Anna

AU - Presti, Maria Laura

AU - Rizzi, Massimo

AU - Samanin, Rosario

AU - Vezzani, Annamaria

PY - 1994/12/12

Y1 - 1994/12/12

N2 - Chronic treatment of adult rats with dl-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic carboxyethylester (CGP 39551) (30 mg/kg orally for 12 days) induced a significant increase, 72 h after the last dose, in the N-methyl-d-aspartate (NMDA)-sensitive [3H]glutamate binding in the hippocampal pyramidal layer (stratum oriens CA1, CA3: + 51% on average; stratum radiatum CA1, CA3: +40% on average; stratum pyramidale CA1: +20%, CA3: + 55%) and in the dentate gyrus (+43%) compared to vehicle-injected animals, as assessed by quantitative receptor autoradiography. Similar results were obtained using the NMDA receptor antagonist, [3H]DL-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 396653). Saturation experiments showed that the increase in [3H]CGP 39653 binding was due to the maximum number of receptors, without changes in affinity. The same regimen did not alter [3H]N-(1-[2-thienyl]-cyclohexyl)-3, 4-piperidine (TCP) binding to the ion channel coupled to the receptor but prevented D-serine (5 μM)-induced enhancement of [3H]glutamate binding. NMDA (3-300 μM) enhanced [3H]noradrenaline release from hippocampal slices, and 7-Cl-kynurenic acid (5-100 μM) and (+)-5-methyl-10, 11-dihydro-5H-dibenzo- [a,d]cyclo-hepten-5, 10-imine maleate (MK 801) (0.03-0.3 μM), antagonists at the glycine site and ion channel respectively, antagonized this effect to the same extent in CGP 39551-treated rats and controls. Chronic CGP 39551 did not affect the neurotoxic potency of quinolinic acid, a selective agonist at the NMDA receptor, injected in the hippocampus. The sensitivity of the NMDA receptor complex to selective agonists or antagonists, thus, does not appear to be altered by chronic treatment with CGP 39551 in adult rats in spite of an increase in the density of the agonist recognition sites. Therefore tolerance is not likely to develop to the pharmacological actions of the drug, and endogenously released excitatory amino acids should not have deleterious effects due to their interaction with a higher amount of NMDA receptors after withdrawal of CGP 39551.

AB - Chronic treatment of adult rats with dl-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic carboxyethylester (CGP 39551) (30 mg/kg orally for 12 days) induced a significant increase, 72 h after the last dose, in the N-methyl-d-aspartate (NMDA)-sensitive [3H]glutamate binding in the hippocampal pyramidal layer (stratum oriens CA1, CA3: + 51% on average; stratum radiatum CA1, CA3: +40% on average; stratum pyramidale CA1: +20%, CA3: + 55%) and in the dentate gyrus (+43%) compared to vehicle-injected animals, as assessed by quantitative receptor autoradiography. Similar results were obtained using the NMDA receptor antagonist, [3H]DL-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP 396653). Saturation experiments showed that the increase in [3H]CGP 39653 binding was due to the maximum number of receptors, without changes in affinity. The same regimen did not alter [3H]N-(1-[2-thienyl]-cyclohexyl)-3, 4-piperidine (TCP) binding to the ion channel coupled to the receptor but prevented D-serine (5 μM)-induced enhancement of [3H]glutamate binding. NMDA (3-300 μM) enhanced [3H]noradrenaline release from hippocampal slices, and 7-Cl-kynurenic acid (5-100 μM) and (+)-5-methyl-10, 11-dihydro-5H-dibenzo- [a,d]cyclo-hepten-5, 10-imine maleate (MK 801) (0.03-0.3 μM), antagonists at the glycine site and ion channel respectively, antagonized this effect to the same extent in CGP 39551-treated rats and controls. Chronic CGP 39551 did not affect the neurotoxic potency of quinolinic acid, a selective agonist at the NMDA receptor, injected in the hippocampus. The sensitivity of the NMDA receptor complex to selective agonists or antagonists, thus, does not appear to be altered by chronic treatment with CGP 39551 in adult rats in spite of an increase in the density of the agonist recognition sites. Therefore tolerance is not likely to develop to the pharmacological actions of the drug, and endogenously released excitatory amino acids should not have deleterious effects due to their interaction with a higher amount of NMDA receptors after withdrawal of CGP 39551.

KW - Autoradiography

KW - Chronic CGP 39551

KW - Hippocampus

KW - NMDA receptor

KW - Quinolinic acid neurotoxicity

KW - [H]Noradrenaline release

UR - http://www.scopus.com/inward/record.url?scp=0027944726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027944726&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(94)90269-0

DO - 10.1016/0014-2999(94)90269-0

M3 - Article

C2 - 7698217

AN - SCOPUS:0027944726

VL - 271

SP - 93

EP - 101

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -